2025 annual financial data
Karyopharm Therapeutics 2025 Operating margin
Direct answer
Operating margin was -62.1%.
Operating income was -90,707,000 USD and net income was -196,039,000 USD.
Operating cash flow was -75,369,000 USD.
Get free Karyopharm Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 146,067,000 USD
- Operating income
- -90,707,000 USD
- Net income
- -196,039,000 USD
- Operating cash flow
- -75,369,000 USD